Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Meera A Srikanthan"'
Autor:
Irene Zolotukhin, David M Markusic, Brett Palaschak, Brad E Hoffman, Meera A Srikanthan, Roland W Herzog
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Hemophilia A and B are coagulation disorders resulting from the loss of functional coagulation factor VIII (FVIII) or factor IX proteins, respectively. Gene therapy for hemophilia with adeno-associated virus vectors has shown efficacy in hemophilia B
Externí odkaz:
https://doaj.org/article/cc6eb2caf37342bfa894aa969350dfa7
Autor:
Meera A. Srikanthan, Olivier Humbert, Kevin G. Haworth, Christina Ironside, Yogendra S. Rajawat, Bruce R. Blazar, Rahul Palchaudhuri, Anthony E. Boitano, Michael P. Cooke, David T. Scadden, Hans-Peter Kiem
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 455-464 (2020)
Conditioning chemotherapy is used to deplete hematopoietic stem cells in the recipient’s marrow, facilitating donor cell engraftment. Although effective, a major issue with chemotherapy is the systemic genotoxicity that increases the risk for secon
Externí odkaz:
https://doaj.org/article/c5914d1b216b478194b953206195ad04
Autor:
Monica S. Thakar, Suzanne Skoda-Smith, Brenda M. Sandmaier, Ann E. Woolfrey, Hans-Peter Kiem, Haydar Frangoul, Aleksandra Petrovic, Kanwaldeep K. Mallhi, Lauri Burroughs, Meera A. Srikanthan, Kelsey Baker, Paul A. Carpenter, Troy R. Torgerson, Amy E. Geddis, K. Scott Baker, Rainer Storb
Publikováno v:
Biol Blood Marrow Transplant
Allogeneic hematopoietic cell transplant (HCT) is often the only curative therapy for patients with nonmalignant diseases; however, many patients do not have an HLA-matched donor. Historically, poor survival has been seen after HLA-haploidentical HCT
Autor:
Anthony E. Boitano, Rahul Palchaudhuri, Hans-Peter Kiem, David T. Scadden, Meera A. Srikanthan, Christina Ironside, Olivier Humbert, Kevin G. Haworth, Bruce R. Blazar, Yogendra S. Rajawat, Michael P. Cooke
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss, Pp 455-464 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Conditioning chemotherapy is used to deplete hematopoietic stem cells in the recipient’s marrow, facilitating donor cell engraftment. Although effective, a major issue with chemotherapy is the systemic genotoxicity that increases the risk for secon
Publikováno v:
Neonatal Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18a8d72920f73b5b10fdfa00b9fd576b
https://doi.org/10.1017/9781108773584.006
https://doi.org/10.1017/9781108773584.006
Autor:
Hans-Peter Kiem, Kevin G. Haworth, Adam J. Hartigan, Rahul Palchaudhuri, Michael P. Cooke, Christina Ironside, Meera A. Srikanthan, Anthony E. Boitano, Jerry Chen
Publikováno v:
Blood. 132:2041-2041
Conditioning chemotherapy is used to deplete hematopoietic stem cells in the recipient's marrow prior to a bone marrow transplant to facilitate engraftment of donor cells. While effective, some major issues with chemotherapy remain which includes off
Autor:
Marc J. Glucksman, Adele J. Wolfson, Michelle M. Song, Lindsay Kua, Jeffrey A. Sigman, Donald E. Elmore, Meera A. Srikanthan, Amanda Pabon, Lisa A. Bruce
Publikováno v:
The FASEB Journal. 21